Motexafin gadolinium prolongs time to neurologic progression in lung cancer patients with brain metastases: results of a randomized phase III trial Article

Mehta, M, Rodrigus, P, Terhaard, C et al. (2002). Motexafin gadolinium prolongs time to neurologic progression in lung cancer patients with brain metastases: results of a randomized phase III trial . INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 54(2), 92. 10.1016/s0360-3016(02)03215-7

cited authors

  • Mehta, M; Rodrigus, P; Terhaard, C; Rao, A; Suh, J; Roa, W; Shapiro, W; Glantz, M; Patchell, R; Weitzner, M; Souhami, L; Bezjak, A; Leibenhaut, M; Komaki, R; Schultz, C; Timmerman, R; Illidge, T; Meyers, C; Curran, W; Phan, S; Smith, J; Miller, RA; Renschler, MF

authors

publication date

  • October 1, 2002

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Lung
  • Lung Cancer
  • Neurosciences

Digital Object Identifier (DOI)

publisher

  • Elsevier

start page

  • 92

volume

  • 54

issue

  • 2